• Explore /
  • Poster
  • / Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.

Abstract Poster

Authors

null

John D. Hainsworth

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

John D. Hainsworth , Joseph Ronald Mace , James Andrew Reeves , Edward J. Crane , Oday Hamid , John R Stille , Amy Flynt , John Polzer , Alvin Milner , Stephanie Roberson , Edward Arrowsmith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01391130

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4547)

DOI

10.1200/jco.2015.33.15_suppl.4547

Abstract #

4547

Poster Bd #

220

Abstract Disclosures

Similar Posters

First Author: Yoshihiko Tomita

First Author: Elizabeth R Kessler

First Author: Paul L. de Souza

First Author: Camila Nassif Martins Ferreira